EGFR and neoplasm: The palmitoylation inhibitor (2-bromopalmitate, 2-BP) or FASN inhibitor (orlistat) can inhibit the stability and activity of EGFR, and weaken downstream signal transduction, thereby inhibiting tumor cell growth and increasing the sensitivity of tumor cells to TKIs 10.